U.S. Meningococcal Vaccines Market Size & Outlook
U.S. meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
U.S. meningococcal vaccines market highlights
- The U.S. meningococcal vaccines market generated a revenue of USD 1,505.6 million in 2021 and is expected to reach USD 2,346.8 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.1% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Bivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 1,505.6 million |
| Market revenue in 2030 | USD 2,346.8 million |
| Growth rate | 5.1% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Bivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, U.S. accounted for 52.3% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 108.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 55.25% in 2021. Horizon Databook has segmented the U.S. meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. dominated the meningococcal vaccine market in 2021 and is projected to continue its dominance over the forecast period owing to presence of key players & favorable reimbursement policies. For instance, CMS provides contract prices for certain large city immunization projects, certain current & former U.S. territories, and state health departments.
Contract prices are lower than private sector prices, which are reported by manufacturers. In addition, rising awareness initiatives undertaken by various organizations, such as Meningitis B Action Project that encourage healthcare providers and young adults to discuss about the vaccine with their families, to create awareness in colleges, campus, & schools drive market growth.
Favorable regulatory scenarios for manufacturers, such as Breakthrough Therapy Designation (BTD) & Fast Track Designation, are likely to boost market growth. For instance, in February 2018, GlaxoSmithKline plc received BTD from the U.S. FDA for Bexsero to prevent Invasive Meningococcal Disease (IMD) caused by serogroup B in children aged 2 to 10.
Reasons to subscribe to U.S. meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into U.S. meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. meningococcal vaccines market size, by type, 2018-2030 (US$M)
U.S. Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
